Infection Prevention and Control Symposium, 8th Biennial - October 20, 2017

As a result of participating in this course, to what extent do you agree that you will be better able to accomplish these objectives *

Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree 0=Not applicable to my practice

	5	4	3	2	1	0
Summarize the development, safety profile and post-marketing monitoring of vaccines.	Summarize the development, safety profile and post-marketing monitoring of vaccines. - 5	Summarize the development, safety profile and post-marketing monitoring of vaccines. - 4	Summarize the development, safety profile and post-marketing monitoring of vaccines. - 3	Summarize the development, safety profile and post-marketing monitoring of vaccines. - 2	Summarize the development, safety profile and post-marketing monitoring of vaccines. - 1	Summarize the development, safety profile and post-marketing monitoring of vaccines. - 0
Analyze the history of vaccines and immunizations to identify familiar patterns and new challenges.	Analyze the history of vaccines and immunizations to identify familiar patterns and new challenges. - 5	Analyze the history of vaccines and immunizations to identify familiar patterns and new challenges. - 4	Analyze the history of vaccines and immunizations to identify familiar patterns and new challenges. - 3	Analyze the history of vaccines and immunizations to identify familiar patterns and new challenges. - 2	Analyze the history of vaccines and immunizations to identify familiar patterns and new challenges. - 1	Analyze the history of vaccines and immunizations to identify familiar patterns and new challenges. - 0
Explain the key components of worldwide research on vaccine development and the future of population-specific targets.	Explain the key components of worldwide research on vaccine development and the future of population-specific targets. - 5	Explain the key components of worldwide research on vaccine development and the future of population-specific targets. - 4	Explain the key components of worldwide research on vaccine development and the future of population-specific targets. - 3	Explain the key components of worldwide research on vaccine development and the future of population-specific targets. - 2	Explain the key components of worldwide research on vaccine development and the future of population-specific targets. - 1	Explain the key components of worldwide research on vaccine development and the future of population-specific targets. - 0
Delineate the wide variety of vaccines and vaccine delivery systems currently available.	Delineate the wide variety of vaccines and vaccine delivery systems currently available. - 5	Delineate the wide variety of vaccines and vaccine delivery systems currently available. - 4	Delineate the wide variety of vaccines and vaccine delivery systems currently available. - 3	Delineate the wide variety of vaccines and vaccine delivery systems currently available. - 2	Delineate the wide variety of vaccines and vaccine delivery systems currently available. - 1	Delineate the wide variety of vaccines and vaccine delivery systems currently available. - 0
Provide patients with information regarding the current status of the global Zika pandemic and address where the highest risks exist for infection and complications.	Provide patients with information regarding the current status of the global Zika pandemic and address where the highest risks exist for infection and complications. - 5	Provide patients with information regarding the current status of the global Zika pandemic and address where the highest risks exist for infection and complications. - 4	Provide patients with information regarding the current status of the global Zika pandemic and address where the highest risks exist for infection and complications. - 3	Provide patients with information regarding the current status of the global Zika pandemic and address where the highest risks exist for infection and complications. - 2	Provide patients with information regarding the current status of the global Zika pandemic and address where the highest risks exist for infection and complications. - 1	Provide patients with information regarding the current status of the global Zika pandemic and address where the highest risks exist for infection and complications. - 0
Delineate the scope of proximal and long-term clinical manifestations and complications of people infected with Zika.	Delineate the scope of proximal and long-term clinical manifestations and complications of people infected with Zika. - 5	Delineate the scope of proximal and long-term clinical manifestations and complications of people infected with Zika. - 4	Delineate the scope of proximal and long-term clinical manifestations and complications of people infected with Zika. - 3	Delineate the scope of proximal and long-term clinical manifestations and complications of people infected with Zika. - 2	Delineate the scope of proximal and long-term clinical manifestations and complications of people infected with Zika. - 1	Delineate the scope of proximal and long-term clinical manifestations and complications of people infected with Zika. - 0
Distinguish and obtain the best available diagnostic methods for Zika and other arboviral diseases.	Distinguish and obtain the best available diagnostic methods for Zika and other arboviral diseases. - 5	Distinguish and obtain the best available diagnostic methods for Zika and other arboviral diseases. - 4	Distinguish and obtain the best available diagnostic methods for Zika and other arboviral diseases. - 3	Distinguish and obtain the best available diagnostic methods for Zika and other arboviral diseases. - 2	Distinguish and obtain the best available diagnostic methods for Zika and other arboviral diseases. - 1	Distinguish and obtain the best available diagnostic methods for Zika and other arboviral diseases. - 0
Address and access data regarding the challenges of currently available medications and the status of development of a safe and effective vaccine.	Address and access data regarding the challenges of currently available medications and the status of development of a safe and effective vaccine. - 5	Address and access data regarding the challenges of currently available medications and the status of development of a safe and effective vaccine. - 4	Address and access data regarding the challenges of currently available medications and the status of development of a safe and effective vaccine. - 3	Address and access data regarding the challenges of currently available medications and the status of development of a safe and effective vaccine. - 2	Address and access data regarding the challenges of currently available medications and the status of development of a safe and effective vaccine. - 1	Address and access data regarding the challenges of currently available medications and the status of development of a safe and effective vaccine. - 0
De-escalate antibiotic usage to optimize clinical outcomes while minimizing toxicity and the emergence of resistance.	De-escalate antibiotic usage to optimize clinical outcomes while minimizing toxicity and the emergence of resistance. - 5	De-escalate antibiotic usage to optimize clinical outcomes while minimizing toxicity and the emergence of resistance. - 4	De-escalate antibiotic usage to optimize clinical outcomes while minimizing toxicity and the emergence of resistance. - 3	De-escalate antibiotic usage to optimize clinical outcomes while minimizing toxicity and the emergence of resistance. - 2	De-escalate antibiotic usage to optimize clinical outcomes while minimizing toxicity and the emergence of resistance. - 1	De-escalate antibiotic usage to optimize clinical outcomes while minimizing toxicity and the emergence of resistance. - 0
Rapidly adjust, change and/or discontinue antibiotic therapy based on clinical and microbiologic evidence and national standards.	Rapidly adjust, change and/or discontinue antibiotic therapy based on clinical and microbiologic evidence and national standards. - 5	Rapidly adjust, change and/or discontinue antibiotic therapy based on clinical and microbiologic evidence and national standards. - 4	Rapidly adjust, change and/or discontinue antibiotic therapy based on clinical and microbiologic evidence and national standards. - 3	Rapidly adjust, change and/or discontinue antibiotic therapy based on clinical and microbiologic evidence and national standards. - 2	Rapidly adjust, change and/or discontinue antibiotic therapy based on clinical and microbiologic evidence and national standards. - 1	Rapidly adjust, change and/or discontinue antibiotic therapy based on clinical and microbiologic evidence and national standards. - 0
Recognize multidrug-resistant organisms (MDROs) and their mechanisms of resistance.	Recognize multidrug-resistant organisms (MDROs) and their mechanisms of resistance. - 5	Recognize multidrug-resistant organisms (MDROs) and their mechanisms of resistance. - 4	Recognize multidrug-resistant organisms (MDROs) and their mechanisms of resistance. - 3	Recognize multidrug-resistant organisms (MDROs) and their mechanisms of resistance. - 2	Recognize multidrug-resistant organisms (MDROs) and their mechanisms of resistance. - 1	Recognize multidrug-resistant organisms (MDROs) and their mechanisms of resistance. - 0
Identify the epidemiologically significant antimicrobial categories of MDROs.	Identify the epidemiologically significant antimicrobial categories of MDROs. - 5	Identify the epidemiologically significant antimicrobial categories of MDROs. - 4	Identify the epidemiologically significant antimicrobial categories of MDROs. - 3	Identify the epidemiologically significant antimicrobial categories of MDROs. - 2	Identify the epidemiologically significant antimicrobial categories of MDROs. - 1	Identify the epidemiologically significant antimicrobial categories of MDROs. - 0
Identify the pathogenesis and epidemiology of tuberculosis in the U.S. and Florida as reported by the Department of Health.	Identify the pathogenesis and epidemiology of tuberculosis in the U.S. and Florida as reported by the Department of Health. - 5	Identify the pathogenesis and epidemiology of tuberculosis in the U.S. and Florida as reported by the Department of Health. - 4	Identify the pathogenesis and epidemiology of tuberculosis in the U.S. and Florida as reported by the Department of Health. - 3	Identify the pathogenesis and epidemiology of tuberculosis in the U.S. and Florida as reported by the Department of Health. - 2	Identify the pathogenesis and epidemiology of tuberculosis in the U.S. and Florida as reported by the Department of Health. - 1	Identify the pathogenesis and epidemiology of tuberculosis in the U.S. and Florida as reported by the Department of Health. - 0
Implement new recommendations concerning airborne isolation utilizing molecular diagnostic techniques and recognize the impact of these new protocols on improving patient care.	Implement new recommendations concerning airborne isolation utilizing molecular diagnostic techniques and recognize the impact of these new protocols on improving patient care. - 5	Implement new recommendations concerning airborne isolation utilizing molecular diagnostic techniques and recognize the impact of these new protocols on improving patient care. - 4	Implement new recommendations concerning airborne isolation utilizing molecular diagnostic techniques and recognize the impact of these new protocols on improving patient care. - 3	Implement new recommendations concerning airborne isolation utilizing molecular diagnostic techniques and recognize the impact of these new protocols on improving patient care. - 2	Implement new recommendations concerning airborne isolation utilizing molecular diagnostic techniques and recognize the impact of these new protocols on improving patient care. - 1	Implement new recommendations concerning airborne isolation utilizing molecular diagnostic techniques and recognize the impact of these new protocols on improving patient care. - 0
Recognize that change is constant in healthcare and we need to explore how adapting to the current healthcare environment will present challenges and opportunities.	Recognize that change is constant in healthcare and we need to explore how adapting to the current healthcare environment will present challenges and opportunities. - 5	Recognize that change is constant in healthcare and we need to explore how adapting to the current healthcare environment will present challenges and opportunities. - 4	Recognize that change is constant in healthcare and we need to explore how adapting to the current healthcare environment will present challenges and opportunities. - 3	Recognize that change is constant in healthcare and we need to explore how adapting to the current healthcare environment will present challenges and opportunities. - 2	Recognize that change is constant in healthcare and we need to explore how adapting to the current healthcare environment will present challenges and opportunities. - 1	Recognize that change is constant in healthcare and we need to explore how adapting to the current healthcare environment will present challenges and opportunities. - 0
Explain what the biggest challenges are, and what we can do to prepare and thrive in this time of uncertainty.	Explain what the biggest challenges are, and what we can do to prepare and thrive in this time of uncertainty. - 5	Explain what the biggest challenges are, and what we can do to prepare and thrive in this time of uncertainty. - 4	Explain what the biggest challenges are, and what we can do to prepare and thrive in this time of uncertainty. - 3	Explain what the biggest challenges are, and what we can do to prepare and thrive in this time of uncertainty. - 2	Explain what the biggest challenges are, and what we can do to prepare and thrive in this time of uncertainty. - 1	Explain what the biggest challenges are, and what we can do to prepare and thrive in this time of uncertainty. - 0

How effective were the following speakers in meeting their learning objectives? *

Scoring key: 5=Very effective, 4= Effective, 3= Somewhat effective, 2= Slightly effective, 1= Completely Ineffective Speakers are listed according to the lecture schedule.

	5	4	3	2	1
Vaccines - Kunjana Mavunda, M.D., MPH, DTM&H	Vaccines - Kunjana Mavunda, M.D., MPH, DTM&H - 5	Vaccines - Kunjana Mavunda, M.D., MPH, DTM&H - 4	Vaccines - Kunjana Mavunda, M.D., MPH, DTM&H - 3	Vaccines - Kunjana Mavunda, M.D., MPH, DTM&H - 2	Vaccines - Kunjana Mavunda, M.D., MPH, DTM&H - 1
Zika Update: Another Great Mimicker - Aileen M. Marty M.D., FCAP	Zika Update: Another Great Mimicker - Aileen M. Marty M.D., FCAP - 5	Zika Update: Another Great Mimicker - Aileen M. Marty M.D., FCAP - 4	Zika Update: Another Great Mimicker - Aileen M. Marty M.D., FCAP - 3	Zika Update: Another Great Mimicker - Aileen M. Marty M.D., FCAP - 2	Zika Update: Another Great Mimicker - Aileen M. Marty M.D., FCAP - 1
Antibiotic Stewardship - Jorge Murillo, M.D., FACP, FIDSA	Antibiotic Stewardship - Jorge Murillo, M.D., FACP, FIDSA - 5	Antibiotic Stewardship - Jorge Murillo, M.D., FACP, FIDSA - 4	Antibiotic Stewardship - Jorge Murillo, M.D., FACP, FIDSA - 3	Antibiotic Stewardship - Jorge Murillo, M.D., FACP, FIDSA - 2	Antibiotic Stewardship - Jorge Murillo, M.D., FACP, FIDSA - 1
Multidrug-Resistant Organisms - Jorge Murillo, M.D., FACP, FIDSA	Multidrug-Resistant Organisms - Jorge Murillo, M.D., FACP, FIDSA - 5	Multidrug-Resistant Organisms - Jorge Murillo, M.D., FACP, FIDSA - 4	Multidrug-Resistant Organisms - Jorge Murillo, M.D., FACP, FIDSA - 3	Multidrug-Resistant Organisms - Jorge Murillo, M.D., FACP, FIDSA - 2	Multidrug-Resistant Organisms - Jorge Murillo, M.D., FACP, FIDSA - 1
Breaking the Chain of Airborne Isolation - David Ashkin, M.D., FCCP and Regina McDade, Ed.D., MPH, BSN, R.N.	Breaking the Chain of Airborne Isolation - David Ashkin, M.D., FCCP and Regina McDade, Ed.D., MPH, BSN, R.N. - 5	Breaking the Chain of Airborne Isolation - David Ashkin, M.D., FCCP and Regina McDade, Ed.D., MPH, BSN, R.N. - 4	Breaking the Chain of Airborne Isolation - David Ashkin, M.D., FCCP and Regina McDade, Ed.D., MPH, BSN, R.N. - 3	Breaking the Chain of Airborne Isolation - David Ashkin, M.D., FCCP and Regina McDade, Ed.D., MPH, BSN, R.N. - 2	Breaking the Chain of Airborne Isolation - David Ashkin, M.D., FCCP and Regina McDade, Ed.D., MPH, BSN, R.N. - 1
Future State of U.S. Healthcare - Ralph Lawson	Future State of U.S. Healthcare - Ralph Lawson - 5	Future State of U.S. Healthcare - Ralph Lawson - 4	Future State of U.S. Healthcare - Ralph Lawson - 3	Future State of U.S. Healthcare - Ralph Lawson - 2	Future State of U.S. Healthcare - Ralph Lawson - 1

Was this course fair, balanced and without commercial bias? *

Yes

How many patients will you see in your practice who will likely be impacted by what you learned at this activity? *

1-5

6-10

Over 10

Not applicable to my practice

Is this your first time attending this symposium? *

Yes

How did you hear about us? *

Would you attend this symposium again next year? *

Yes

If you checked "No,” please tell us why: *

If you checked "No,” please explain why you would not recommend this course: *

What do you intend to do differently in the treatment of your patients as a result of what you learned? What new strategies will you apply in your practice of patient care? *

If you do not plan to implement any new strategies learned, please list any barriers or obstacles that might keep you from doing so.

Suggested topics and/or speakers you would like for future symposiums.

Comments

Name

Leave this field blank

You are here

Infection Prevention and Control Symposium, 8th Biennial - October 20, 2017